David W Vredevoogd
Overview
Explore the profile of David W Vredevoogd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
521
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vredevoogd D, Apriamashvili G, Levy P, Sinha S, Huinen Z, Visser N, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39510795
Background: Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression on CD8 T...
2.
Lin C, Levy P, Alflen A, Apriamashvili G, Ligtenberg M, Vredevoogd D, et al.
Cancer Cell
. 2024 Mar;
42(4):623-645.e10.
PMID: 38490212
Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been systematically studied whether there are regulators that uniquely or broadly contribute to T cell fitness....
3.
Vredevoogd D, Peeper D
Front Immunol
. 2023 Jul;
14:1162706.
PMID: 37398651
Functional genetic screens to uncover tumor-intrinsic nodes of immune resistance have uncovered numerous mechanisms by which tumors evade our immune system. However, due to technical limitations, tumor heterogeneity is imperfectly...
4.
Kenski J, Huang X, Vredevoogd D, de Bruijn B, Traets J, Ibanez-Molero S, et al.
Cell Rep Med
. 2023 Feb;
4(2):100941.
PMID: 36812891
By restoring tryptophan, indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors aim to reactivate anti-tumor T cells. However, a phase III trial assessing their clinical benefit failed, prompting us to revisit the role...
5.
Boshuizen J, Vredevoogd D, Krijgsman O, Ligtenberg M, Blankenstein S, de Bruijn B, et al.
Nat Commun
. 2023 Feb;
14(1):672.
PMID: 36750559
No abstract available.
6.
TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling
Lin C, Traets J, Vredevoogd D, Visser N, Peeper D
EMBO J
. 2023 Jan;
42(5):e111614.
PMID: 36715448
Resistance to cancer immunotherapy continues to impair common clinical benefit. Here, we use whole-genome CRISPR-Cas9 knockout data to uncover an important role for Tuberous Sclerosis Complex 2 (TSC2) in determining...
7.
Zhang Z, Kong X, Ligtenberg M, van Hal-van Veen S, Visser N, de Bruijn B, et al.
Cell Rep Med
. 2022 Jun;
3(6):100655.
PMID: 35688159
Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation, diminishing adaptive CD8 T cell antitumor activity. Although innate natural killer (NK) cells are triggered by loss of MHC class...
8.
Apriamashvili G, Vredevoogd D, Krijgsman O, Bleijerveld O, Ligtenberg M, de Bruijn B, et al.
Nat Commun
. 2022 Apr;
13(1):1923.
PMID: 35395848
The cytokine IFNγ differentially impacts on tumors upon immune checkpoint blockade (ICB). Despite our understanding of downstream signaling events, less is known about regulation of its receptor (IFNγ-R1). With an...
9.
Vredevoogd D, Peeper D
Science
. 2021 Sep;
373(6559):1088-1089.
PMID: 34516853
Melanoma can arise only from cells with a permissive chromatin landscape.
10.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd D, Rozeman E, Ibanez Molero S, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5389-5400.
PMID: 34230026
Purpose: Combining anti-PD-1 + anti-CTLA-4 immune-checkpoint blockade (ICB) shows improved patient benefit, but it is associated with severe immune-related adverse events and exceedingly high cost. Therefore, there is a dire...